Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma.
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation. He received consolidation radiotherapy on the site of bulky disease. At 20 months from transplant, the disease is in continuous complete remission. The successful use of pixantrone as a bridge to transplant is highlighted, together with the absence of serious side effects.
Oncology-Hematology Unit, ASST Valle Olona, Busto Arsizio, Italy.
Lorena
L
Appio
Carlo
C
Landoni
Maria
M
La Targia
Vanda
V
Bertolli
Martina
M
Chiarucci
Giovanni
G
Crovetti
Elisabetta
E
Vassenna
Giovanni
G
Serio
Marco
M
Bregni
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007546:Isoquinolines / Q000627:therapeutic use*; D008198:Lymph Nodes / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab / Q000008:administration & dosage; D059005:Topoisomerase II Inhibitors / Q000627:therapeutic use*; D014182:Transplantation, Autologous; D016277:Ventricular Function, Left; D014750:Vincristine / Q000008:administration & dosage
D007546:Isoquinolines; D059005:Topoisomerase II Inhibitors; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C086548:pixantrone; D011241:Prednisone